[New data on sensibilizing therapy of alcoholic dependence].
Lidevine was used in the treatment of 29 patients with chronic alcoholism with unsatisfactory results of previous therapy. The drug was included in the complex therapy at the stage of developing therapeutic remission and during a long-term (1 year) antirelapse treatment. Remission of 1-year duration was achieved in 12 (41%) patients. Use of lidevine contributes to remission stabilization and prevents development of alcoholism relapse after a single "break down". The importance of lidevine assignment in combination with psychopharmacological drugs reducing a drive for alcohol (antidepressants, anticonvulsants-normotimics, neuroleptics with sedative action, etc.), and a need of continuous control of the relatives of the patient over the intake of sensibilazing drug are proved. Good tolerance to the medication is shown.
Ivanets
N N
NN
Kinkul'kina
M A
MA
D000225:Adenine / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy*; D004221:Disulfiram / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000427:Alcohol Deterrents; D004338:Drug Combinations; D009536:Niacinamide; D000225:Adenine; D004221:Disulfiram